

# Francois Ducray

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6295770/publications.pdf>

Version: 2024-02-01

158  
papers

7,111  
citations

81434

41  
h-index

75989

78  
g-index

176  
all docs

176  
docs citations

176  
times ranked

9518  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics and management of hydrocephalus in adult patients with cerebellar glioblastoma: lessons from a French nationwide series of 118 cases. <i>Neurosurgical Review</i> , 2022, 45, 683-699.	1.2	4
2	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	0.6	25
3	Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfilER trial. <i>Medical Oncology</i> , 2022, 39, 4.	1.2	3
4	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 414-423.	1.9	3
5	Gyriform infiltration as imaging biomarker for molecular glioblastomas. <i>Journal of Neuro-Oncology</i> , 2022, 157, 511-521.	1.4	9
6	Clinical and pathological impact of an optimal assessment of brain invasion for grade 2 meningioma diagnosis: lessons from a series of 291 cases. <i>Neurosurgical Review</i> , 2022, 45, 2797-2809.	1.2	3
7	Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. <i>Neurology</i> , 2021, 96, e866-e875.	1.5	44
8	Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab078.	0.4	2
9	Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab061.	0.4	28
10	Management, functional outcomes and survival in a French multicentric series of 118 adult patients with cerebellar glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1843-1856.	1.2	5
11	Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. <i>Journal of Neurology</i> , 2021, 268, 2515-2522.	1.8	4
12	Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for <i>IDH</i> -Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. <i>Oncologist</i> , 2021, 26, e838-e846.	1.9	10
13	Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. <i>Journal of Neuro-Oncology</i> , 2021, 153, 55-64.	1.4	8
14	TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. <i>Oncologist</i> , 2021, 26, 647-e1304.	1.9	3
15	Intracranial non-myxoid angiomatoid fibrous histiocytoma with <i>EWSR1</i> - <i>CREB1</i> transcript fusion treated with doxorubicin: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 131.	0.4	5
16	Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> V600E-Mutant Adult Glial and Glioneuronal Tumors. <i>Neurology</i> , 2021, 97, e673-e683.	1.5	16
17	Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients. <i>Neuro-Oncology Practice</i> , 2021, 8, 148-159.	1.0	2
18	Alterations of cerebral microcirculation in peritumoral edema: feasibility of in vivo sidestream dark-field imaging in intracranial meningiomas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa108.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. <i>Neuro-Oncology</i> , 2020, 22, 1614-1624.	0.6	41
20	Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 106006.	0.6	7
21	Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients. <i>Neurosurgery</i> , 2020, 87, E513-E519.	0.6	10
22	Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	58
23	Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. <i>Journal of Neurology</i> , 2020, 267, 2083-2089.	1.8	28
24	Central nervous system complications associated with immune checkpoint inhibitors. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 772-778.	0.9	92
25	Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	129
26	CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2019, 21, 1519-1528.	0.6	107
27	The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 175.	2.4	8
28	Highlights of the inaugural ten " the launch of <i>Neuro-Oncology Advances</i> . <i>Neuro-Oncology Advances</i> , 2019, 1, vdz016.	0.4	0
29	Letter to the Editor. <i>Neuro-Oncology</i> , 2019, 21, 1482-1482.	0.6	0
30	Conventional MRI radiomics in patients with suspected early- or pseudo-progression. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz019.	0.4	14
31	Multinodular and Vacuolating Posterior Fossa Lesions of Unknown Significance. <i>American Journal of Neuroradiology</i> , 2019, 40, 1689-1694.	1.2	10
32	Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients. <i>Revue Neurologique</i> , 2019, 175, 534-543.	0.6	8
33	Charcot-Marie-Tooth (CMT)-like polyneuropathy revealing neurofibromatosis type 2: A case report and review of the literature. <i>Revue Neurologique</i> , 2019, 175, 486-489.	0.6	2
34	A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549" BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 537-545.	1.6	1
35	Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. <i>Journal of Neuro-Oncology</i> , 2019, 143, 515-523.	1.4	11
36	Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2019, 9, 177.	1.3	17

#	ARTICLE	IF	CITATIONS
37	Simultaneous occurrence of giant cell arteritis and cerebral amyloid angiopathy. <i>Rheumatology</i> , 2019, 58, 1503-1505.	0.9	1
38	Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations. <i>Neurosurgery</i> , 2019, 85, E448-E456.	0.6	20
39	Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis. <i>Journal of Neurology</i> , 2019, 266, 195-206.	1.8	58
40	Stroke-like events after brain radiotherapy: a large series with long-term follow-up. <i>European Journal of Neurology</i> , 2019, 26, 639-650.	1.7	29
41	The molecular landscape of glioma in patients with Neurofibromatosis 1. <i>Nature Medicine</i> , 2019, 25, 176-187.	15.2	145
42	Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. <i>Journal of Neurology</i> , 2019, 266, 398-410.	1.8	31
43	A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: An ANOCEF trial (DXA). <i>Neuro-Oncology Advances</i> , 2019, 1, vdz043.	0.4	8
44	IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. <i>Neuro-Oncology</i> , 2018, 20, 716-718.	0.6	8
45	Glioblastoma as differential diagnosis of autoimmune encephalitis. <i>Journal of Neurology</i> , 2018, 265, 669-677.	1.8	30
46	Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. <i>Journal of Neuro-Oncology</i> , 2018, 138, 141-145.	1.4	6
47	Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 789-792.	0.9	41
48	Characteristics of cerebellar glioblastomas in adults. <i>Journal of Neuro-Oncology</i> , 2018, 136, 555-563.	1.4	31
49	Intravascular large B-cell lymphoma mimicking cerebral amyloid angiopathy-related inflammation. <i>Revue Neurologique</i> , 2018, 174, 265-266.	0.6	6
50	Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. <i>Journal of Neuro-Oncology</i> , 2018, 136, 533-539.	1.4	16
51	Molecular classification of adult gliomas: recent advances and future perspectives. <i>Current Opinion in Oncology</i> , 2018, 30, 375-382.	1.1	7
52	Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. <i>Acta Neuropathologica Communications</i> , 2018, 6, 89.	2.4	12
53	Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma. <i>Oncologist</i> , 2018, 23, 1500-1510.	1.9	6
54	Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. <i>Journal of Neurology</i> , 2018, 265, 2190-2200.	1.8	64

#	ARTICLE	IF	CITATIONS
55	Motor neuron disease of paraneoplastic origin: a rare but treatable condition. <i>Journal of Neurology</i> , 2018, 265, 1590-1599.	1.8	31
56	Returning to work after multimodal treatment in glioblastoma patients. <i>Neurosurgical Focus</i> , 2018, 44, E17.	1.0	29
57	Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. <i>Neurology</i> , 2017, 88, 514-524.	1.5	49
58	Brain Gliomas in the Elderly. , 2017, , 119-140.		0
59	Characteristics of H3 K27M-mutant gliomas in adults. <i>Neuro-Oncology</i> , 2017, 19, 1127-1134.	0.6	207
60	Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 347-358.	1.0	24
61	Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. <i>European Journal of Cancer</i> , 2017, 72, 12-19.	1.3	14
62	Anaplastic gliomas in adults: an update. <i>Current Opinion in Oncology</i> , 2017, 29, 434-442.	1.1	10
63	Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2017, 4, e371.	3.1	64
64	Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas. <i>Brain Pathology</i> , 2017, 27, 567-579.	2.1	16
65	Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. <i>Cancer Biomarkers</i> , 2017, 20, 435-441.	0.8	13
66	Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. <i>Cancer Medicine</i> , 2016, 5, 1753-1764.	1.3	12
67	Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. <i>Neuro-Oncology</i> , 2016, 18, 888-890.	0.6	16
68	The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1129-1136.	0.6	85
69	Neuroleptic intolerance in patients with anti-NMDAR encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e280.	3.1	139
70	Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. <i>Acta Neuropathologica</i> , 2016, 132, 625-634.	3.9	85
71	Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures. <i>JAMA Neurology</i> , 2016, 73, 1115.	4.5	155
72	Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. <i>Nature Communications</i> , 2016, 7, 11263.	5.8	73

#	ARTICLE	IF	CITATIONS
73	Characteristics of gliomas in patients with somatic IDH mosaicism. <i>Acta Neuropathologica Communications</i> , 2016, 4, 31.	2.4	29
74	Anti-NMDA-R encephalitis: Should we consider extreme delta brush as electrical status epilepticus?. <i>Neurophysiologie Clinique</i> , 2016, 46, 17-25.	1.0	32
75	Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 47-53.	0.7	15
76	Pseudotumoral presentation of cerebral amyloid angiopathy-related inflammation. <i>Neurology</i> , 2016, 86, 912-919.	1.5	33
77	Bevacizumab in late-onset radiation-induced myelopathy. <i>Neurology</i> , 2016, 86, 454-457.	1.5	24
78	Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. <i>Oncotarget</i> , 2016, 7, 61916-61929.	0.8	42
79	Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 728-737.	1.3	18
80	Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. <i>Computational and Mathematical Methods in Medicine</i> , 2015, 2015, 1-7.	0.7	9
81	Treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor encephalitis. <i>Journal of Neurology</i> , 2015, 262, 1859-1866.	1.8	105
82	CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2015, 17, 1497-1503.	0.6	52
83	Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome. <i>Neurology</i> , 2015, 85, 2076-2078.	1.5	28
84	CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e166.	3.1	18
85	Input of molecular analysis in medical management of primary brain tumor patients. <i>Revue Neurologique</i> , 2015, 171, 457-465.	0.6	2
86	CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling. <i>Cancer Research</i> , 2015, 75, 3519-3528.	0.4	35
87	Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. <i>Journal of Neuro-Oncology</i> , 2015, 122, 529-537.	1.4	12
88	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. <i>Neurology</i> , 2015, 85, 1325-1331.	1.5	34
89	Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone. <i>Journal of Neurosurgery</i> , 2015, 123, 1244-1246.	0.9	5
90	C inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. <i>Annals of Neurology</i> , 2015, 78, 355-374.	2.8	71

#	ARTICLE	IF	CITATIONS
91	Clinical Spectrum of Encephalitis Associated With Antibodies Against the Î±-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor. <i>JAMA Neurology</i> , 2015, 72, 1163.	4.5	123
92	TCF12 is mutated in anaplastic oligodendroglioma. <i>Nature Communications</i> , 2015, 6, 7207.	5.8	42
93	VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 121, 499-504.	1.4	29
94	Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution. <i>Blood</i> , 2015, 126, 1544-1544.	0.6	2
95	Treating glioblastoma patients with poor performance status: where do we go from here?. <i>CNS Oncology</i> , 2014, 3, 231-241.	1.2	3
96	An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	8
97	Seronegative paraneoplastic cerebellar degeneration: the <sc>PNS E</sc>uronetwork experience. <i>European Journal of Neurology</i> , 2014, 21, 731-735.	1.7	46
98	Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. <i>Neuro-Oncology</i> , 2014, 16, 1244-1254.	0.6	47
99	Progressive multifocal leukoencephalopathy in patients with sarcoidosis. <i>Neurology</i> , 2014, 82, 1307-1313.	1.5	43
100	Pontine infarction responsible for wall-eyed bilateral internuclear ophthalmoplegia syndrome. <i>Neurology: Clinical Practice</i> , 2014, 4, 524-525.	0.8	2
101	Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. <i>Neuro-Oncology</i> , 2014, 16, 662-670.	0.6	59
102	Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 642-648.	0.7	8
103	Patterns of care and survival of glioblastoma patients: A comparative study between 2004 and 2008 in Lyon, France. <i>Revue Neurologique</i> , 2014, 170, 222-227.	0.6	6
104	Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. <i>Neurosurgical Review</i> , 2014, 37, 415-424.	1.2	37
105	Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. <i>Neurology</i> , 2014, 82, 556-563.	1.5	202
106	Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis. <i>Journal of Infection</i> , 2014, 68, 419-425.	1.7	19
107	An overview of current and future treatment options for adults anaplastic oligodendroglial tumors. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 831-840.	0.5	0
108	Anaplastic oligodendrogliomasâ€™ value of early chemotherapy. <i>Nature Reviews Neurology</i> , 2013, 9, 7-8.	4.9	3

#	ARTICLE	IF	CITATIONS
109	Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy. <i>Journal of Neuro-Oncology</i> , 2013, 115, 261-265.	1.4	6
110	Dramatic improvement after rituximab in a patient with paraneoplastic treatmentâ€refractory <scp>M</scp>orvan syndrome associated with antiâ€<scp>CASPR</scp>2 antibodies. <i>European Journal of Neurology</i> , 2013, 20, e96-7.	1.7	23
111	Ventriculitis revealing Bing-Neel syndrome in a patient without Waldenstrom's macroglobulinemia. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 82-84.	0.6	10
112	Choosing the tumoral epilepsy surgery candidate. <i>Epilepsia</i> , 2013, 54, 91-96.	2.6	7
113	Predictive biomarkers in adult gliomas. <i>Current Opinion in Oncology</i> , 2013, 25, 689-694.	1.1	34
114	Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. <i>Neurology</i> , 2013, 80, 2226-2232.	1.5	68
115	Acute late-onset encephalopathy after radiotherapy: An unusual life-threatening complication. <i>Neurology</i> , 2013, 81, 1014-1017.	1.5	25
116	Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse. <i>Blood</i> , 2013, 122, 933-933.	0.6	1
117	Anti-NMDA receptor encephalitis mimicking a primary psychiatric disorder in a 13-year-old girl. <i>Turk Psikiyatri Dergisi</i> , 2013, 24, 145-7.	0.2	0
118	Chemotherapy in low-grade gliomas. <i>Current Opinion in Oncology</i> , 2012, 24, 694-701.	1.1	30
119	A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy. <i>Clinical Cancer Research</i> , 2012, 18, 5071-5080.	3.2	103
120	Quantitative Morphological Magnetic Resonance Imaging Follow-up of Low-Grade Glioma. <i>Neurosurgery</i> , 2012, 71, 729-740.	0.6	116
121	Primary brain tumours in adults. <i>Lancet, The</i> , 2012, 379, 1984-1996.	6.3	723
122	Increased rCBV in status epilepticus. <i>Journal of Neurology</i> , 2012, 259, 1746-1748.	1.8	1
123	Cortical and Subventricular Zone Glioblastoma-Derived Stem-Like Cells Display Different Molecular Profiles and Differential In Vitro and In Vivo Properties. <i>Annals of Surgical Oncology</i> , 2012, 19, 608-619.	0.7	32
124	SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas. <i>PLoS ONE</i> , 2012, 7, e45950.	1.1	25
125	Antiâ€<i>N</i>â€methylâ€Dâ€aspartate receptor encephalitis with acute disseminated encephalomyelitisâ€like MRI features. <i>European Journal of Neurology</i> , 2012, 19, e16-7.	1.7	36
126	New targeted therapies in pituitary carcinoma resistant to temozolomide. <i>Pituitary</i> , 2012, 15, 37-43.	1.6	87



#	ARTICLE	IF	CITATIONS
127	Chemotherapy for diffuse low-grade gliomas in adults. <i>Revue Neurologique</i> , 2011, 167, 673-679.	0.6	8
128	Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. <i>European Journal of Cancer</i> , 2011, 47, 802-808.	1.3	39
129	Predictive and prognostic factors for gliomas. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 781-789.	1.1	54
130	Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 457-462.	1.4	26
131	Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression. <i>Journal of Neuro-Oncology</i> , 2011, 105, 219-224.	1.4	36
132	Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. <i>Journal of Neurology</i> , 2011, 258, 328-329.	1.8	28
133	Encéphalites auto-immunes à anticorps anti-récepteurs-NMDA, une cause fréquente d'encéphalite en réanimation. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2011, 20, 397-407.	0.1	2
134	Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. <i>Cancer</i> , 2011, 117, 3014-3026.	2.0	32
135	Peri-ictal pseudoprogression in patients with brain tumor. <i>Neuro-Oncology</i> , 2011, 13, 775-782.	0.6	38
136	Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3050-3055.	0.8	196
137	Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. <i>Neuro-Oncology</i> , 2011, 13, 84-98.	0.6	115
138	Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade. <i>Journal of Neuro-Oncology</i> , 2010, 97, 353-364.	1.4	26
139	Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. <i>Journal of Neuro-Oncology</i> , 2010, 100, 439-441.	1.4	15
140	Delayed onset of a second paraneoplastic neurological syndrome in eight patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 937-939.	0.9	31
141	Prognostic markers in gliomas. <i>Future Oncology</i> , 2010, 6, 733-739.	1.1	17
142	Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. <i>Neuro-Oncology</i> , 2010, 12, 1078-1082.	0.6	81
143	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. <i>Molecular Cancer</i> , 2010, 9, 234.	7.9	37
144	Acute Headache Followed by Focal Neuropsychological Impairment in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2010, 19, 75-76.	0.7	4

#	ARTICLE	IF	CITATIONS
145	Glioblastomes: aspects moléculaires et prise en charge actuelle. <i>Oncologie</i> , 2009, 11, 67-71.	0.2	1
146	Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 4150-4154.	0.8	887
147	Diagnostic and prognostic markers in gliomas. <i>Current Opinion in Oncology</i> , 2009, 21, 537-542.	1.1	40
148	Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center.. <i>Blood</i> , 2009, 114, 2702-2702.	0.6	0
149	Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status. <i>Journal of Neuro-Oncology</i> , 2008, 88, 185-188.	1.4	10
150	Genomic changes in progression of low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 90, 133-140.	1.4	51
151	Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. <i>Molecular Cancer</i> , 2008, 7, 41.	7.9	145
152	Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors. <i>Oncologist</i> , 2008, 13, 978-992.	1.9	48
153	Postradiation lumbosacral radiculopathy with spinal root cavernomas mimicking carcinomatous meningitis. <i>Neuro-Oncology</i> , 2008, 10, 1035-1039.	0.6	29
154	Molecular genetic markers as predictors of response to chemotherapy in gliomas. <i>Current Opinion in Oncology</i> , 2007, 19, 606-611.	1.1	56
155	TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 103-107.	1.0	15
156	No association of MDM2 SNP309 with risk of glioblastoma and prognosis. <i>Journal of Neuro-Oncology</i> , 2007, 85, 241-244.	1.4	14
157	Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 325-327.	0.9	41
158	IQGAP1 Protein Specifies Amplifying Cancer Cells in Glioblastoma Multiforme. <i>Cancer Research</i> , 2006, 66, 9074-9082.	0.4	50